Ohm wrote, A few million dollars isn't much in
Post# of 148185
Quote:
A few million dollars [for the cost of a Phase III liver trial] isn't much in the scheme of things. 20% or more of revenue up and above what simple distribution would cost on a multi-billion dollar indication is.
Very true, but if you are putting money upfront, and don't have much or any revenue yet, I don't think some backing + cash in the form of a NASH partnership would be a bad thing. As Ohm has shown, there are so many possible indications, down the road, and such a vast market awaiting, that sacrificing a portion of one of those markets might make sense. If CYDY can go it alone, without toxic financing, so much the better. Just need revenue, either via partnership or approval.